These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12067682)

  • 1. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
    O'Regan RM; Jordan VC
    Lancet Oncol; 2002 Apr; 3(4):207-14. PubMed ID: 12067682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
    Bentrem DJ; Jordan VC
    Curr Opin Obstet Gynecol; 2002 Feb; 14(1):5-12. PubMed ID: 11801870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
    Twombly R
    J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New developments in the hormonal treatment of breast cancer in postmenopausal women].
    Trunet P; Marty M
    Bull Cancer; 1999 Oct; 86(10):815-20. PubMed ID: 10572232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
    Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
    Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
    Robertson JF
    Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oestrogen receptor and its selective modulators in gynaecological and breast cancer.
    Vergote I; Neven P; van Dam P; Serreyn R; De Prins F; De Sutter P; Albertyn G
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S1-9. PubMed ID: 11056296
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel agents to modulate oestrogen action.
    Dardes RC; Jordan VC
    Br Med Bull; 2000; 56(3):773-86. PubMed ID: 11255561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment guideline for breast cancer and SERM-treatment].
    Iwase H; Yamamoto Y; Kawasoe T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():636-40. PubMed ID: 18159717
    [No Abstract]   [Full Text] [Related]  

  • 16. The endocrine prevention of breast cancer.
    Howell A
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
    Miller WR; Bartlett JM; Canney P; Verrill M
    Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
    Lo SS; Vogel VG
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.